ArticleIDCases2025
Primary herpes Simplex Virus type 1 pneumonitis in a patient after bilateral lung transplantation.
Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Herpes Simplex Virus type 1 (HSV-1) can cause disseminated, systemic infections in immunocompromised patients. HSV-1 pneumonitis is a rare pulmonary infection that is associated with high morbidity and mortality. There is a dearth of published literature on clinical characteristics and outcomes of primary HSV-1 pneumonitis in lung transplant recipients. Clinical case: We describe case of primary HSV-1 infection in an immunocompromised patient immediately after lung transplantation. The infection resulted in fulminant pneumonitis that progressed rapidly, causing refractory hypoxia requiring prolonged mechanical ventilation and veno-venous extra-corporeal membrane oxygenation (VV-ECMO) support. The HSV-1 pneumonitis was successfully treated with antiviral therapy and supportive care, and the patient was discharged home on room air. Discussion: HSV-1 pneumonitis can be associated with fulminant course associated in immunocompromised patients with high morbidity and mortality. Prompt diagnosis and aggressive treatment is necessary for a successful outcome. In lung transplant recipients, HSV-1 pneumonitis can be associated with de novo donor specific antibodies (DSAs) and early graft loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.